Aug 2026· Cancers· Vol 18· 0 citations· 55 references
Medicine
TL;DR
It is suggested that the LINC01446/miR-338-3p/APEX1 axis may contribute to ESCC progression and ferroptosis defense, warranting further investigation into its potential therapeutic and prognostic value.
Abstract
Simple Summary Esophageal squamous cell carcinoma (ESCC) is an aggressive malignancy with a poor prognosis, highlighting the urgent need to elucidate its molecular mechanisms to develop targeted therapies. Long non-coding RNAs (lncRNAs) play a critical role in cancer progression. However, the majority of lncRNAs involved in ESCC progression remain to be elucidated. This study aimed to investigate the expression and role of LINC01446 in ESCC, particularly its involvement in tumor progression and ferroptosis defense. Based on bioinformatics analysis of the TCGA and GEO datasets, LINC01446 was significantly upregulated in ESCC and correlated with poorer overall survival (OS). Functional assays revealed that LINC01446 knockdown suppressed ESCC cell proliferation, migration, and invasion. In addition, its knockdown induced ferroptosis in ESCC cells, as evidenced by elevated oxidized C11-BODIPY staining, increased malondialdehyde (MDA) levels, and decreased glutathione (GSH) levels. Mechanistically, apurinic/apyrimidinic endodeoxyribonuclease 1 (APEX1) was identified as a downstream target of LINC01446 using RNA sequencing and Western blotting, the expression of which was positively correlated in ESCC tissues. Further experiments suggested that cytoplasmic LINC01446 might act as a competing endogenous RNA (ceRNA) that sponges miR-338-3p, thereby alleviating its repressive effect on APEX1 expression. Dual-luciferase and AGO2-RIP assays supported a regulatory relationship among LINC01446, miR-338-3p, and APEX1, consistent with a ceRNA-mediated mechanism. Moreover, LINC01446 knockdown suppressed tumor growth and reduced APEX1 expression in vivo, accompanied by increased MDA levels, suggesting enhanced lipid peroxidation and a possible increase in ferroptosis. These findings suggest that the LINC01446/miR-338-3p/APEX1 axis may contribute to ESCC progression and ferroptosis defense, warranting further investigation into its potential therapeutic and prognostic value.
DLGAP1-AS2 acts as a potential biomarker for unfavorable prognosis in ESCC patients and promotes malignant phenotypes of ESCC cells in vitro by regulating the miR-101-3p/EZH2 axis, enhancing proliferation and EMT, while suppressing ferroptosis.
CASC9 functions as an oncogenic lncRNA that promotes ESCC progression by modulating ferroptosis, representing a promising early diagnostic biomarker, prognostic predictor, and therapeutic target.
It is suggested that UPK1A-AS1 is a hypoxia‐inducible oncogenic lncRNA that plays dual roles in cancer, with cancer type‐dependent associations with progression and immune modulation across malignancies and mechanistically mediating hypoxia‐associated drug resistance in HCC.
Ze-Kai Li, Min Luo, Shu-Sen Fang et al.· Analytical Cellular Patholog...· 0 citations
It is revealed that the LINC02038/miR‐506‐3p/ATP7A axis played a crucial oncogenic role in HCC by driving tumor progression and modulating cuproptosis, and represents a promising prognostic biomarker and a potential therapeutic target for HCC intervention.
Zhe Liu, Weixi Shan, Wen-Yu Zhou et al.· Journal of biochemical and m...· 0 citations
It is found that KAT2B transcriptionally activates GSTZ1 in a H3K9ac-dependent manner, which in turn inhibits GPX4 expression, thereby suppressing OSCC proliferation and stemness while enhancing ferroptosis sensitivity.
Tong Sha, Kun Jiao, Jia-Ning Li et al.· Biochemical Pharmacology· 0 citations
It is suggested that SOX2OT contributes to NSCLC pathogenesis through regulation of a miR-143-centered signaling network that influences oncogenic signaling, cellular survival, and metastatic potential, while also underscoring the broader importance of lncRNA-mediated post-transcriptional regulation in lung cancer biol...
M. Zarei, Elahe Asadollahi, Babak Jahangiri et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.